Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
In the latest session, 10x Genomics Inc (NASDAQ: TXG) closed at $18.75 down -1.68% from its previous closing price of $19.07. In other words, the price has decreased by -$1.68 from its previous closing price. On the day, 3.16 million shares were traded. TXG stock price reached its highest trading level at $19.18 during the session, while it also had its lowest trading level at $18.47.
Ratios:
For a deeper understanding of 10x Genomics Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.92 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 32.49. For the most recent quarter (mrq), Quick Ratio is recorded 4.06 and its Current Ratio is at 4.48. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on September 11, 2025, initiated with a Neutral rating and assigned the stock a target price of $15.
On February 13, 2025, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $25 to $12.
On September 03, 2024, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $35.Leerink Partners initiated its Outperform rating on September 03, 2024, with a $35 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Nov 24 ’25 when Taich Adam sold 11,888 shares for $19.00 per share. The transaction valued at 225,852 led to the insider holds 297,385 shares of the business.
Hindson Benjamin J. sold 8,283 shares of TXG for $157,363 on Nov 24 ’25. The insider now owns 432,605 shares after completing the transaction at $19.00 per share. On Nov 24 ’25, another insider, Saxonov Serge, who serves as the Chief Executive Officer of the company, sold 13,261 shares for $19.00 each. As a result, the insider received 251,936 and left with 1,021,556 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TXG now has a Market Capitalization of 2372869632 and an Enterprise Value of 1977770752. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.70 while its Price-to-Book (P/B) ratio in mrq is 3.02. Its current Enterprise Value per Revenue stands at 3.082 whereas that against EBITDA is -20.285.
Stock Price History:
The Beta on a monthly basis for TXG is 2.09, which has changed by 0.17924523 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, TXG has reached a high of $20.34, while it has fallen to a 52-week low of $6.78. The 50-Day Moving Average of the stock is 36.01%, while the 200-Day Moving Average is calculated to be 60.77%.
Shares Statistics:
For the past three months, TXG has traded an average of 2.82M shares per day and 3444700 over the past ten days. A total of 116.46M shares are outstanding, with a floating share count of 111.94M. Insiders hold about 11.55% of the company’s shares, while institutions hold 96.85% stake in the company. Shares short for TXG as of 1763078400 were 15501651 with a Short Ratio of 5.50, compared to 1760486400 on 12546318. Therefore, it implies a Short% of Shares Outstanding of 15501651 and a Short% of Float of 19.469998999999998.
Earnings Estimates
The stock of 10x Genomics Inc (TXG) is currently drawing attention from 3.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.18, with high estimates of -$0.08 and low estimates of -$0.28.
Analysts are recommending an EPS of between $0.46 and -$0.49 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is -$0.41, with 3.0 analysts recommending between -$0.08 and -$0.9.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $156M this quarter.It ranges from a high estimate of $157.19M to a low estimate of $154.1M. As of. The current estimate, 10x Genomics Inc’s year-ago sales were $165.02MFor the next quarter, 15 analysts are estimating revenue of $142.61M. There is a high estimate of $149.1M for the next quarter, whereas the lowest estimate is $135.85M.
A total of 16 analysts have provided revenue estimates for TXG’s current fiscal year. The highest revenue estimate was $633.99M, while the lowest revenue estimate was $586.82M, resulting in an average revenue estimate of $629.93M. In the same quarter a year ago, actual revenue was $610.78MBased on 16 analysts’ estimates, the company’s revenue will be $610.58M in the next fiscal year. The high estimate is $621.3M and the low estimate is $596M.
